AU2001232031A1 - Novel uses of polyanionic polyglycosides in treating gut disorders - Google Patents

Novel uses of polyanionic polyglycosides in treating gut disorders

Info

Publication number
AU2001232031A1
AU2001232031A1 AU2001232031A AU3203101A AU2001232031A1 AU 2001232031 A1 AU2001232031 A1 AU 2001232031A1 AU 2001232031 A AU2001232031 A AU 2001232031A AU 3203101 A AU3203101 A AU 3203101A AU 2001232031 A1 AU2001232031 A1 AU 2001232031A1
Authority
AU
Australia
Prior art keywords
novel uses
gut disorders
polyanionic
polyglycosides
treating gut
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001232031A
Inventor
Stephen Dealler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Norton Healthcare Ltd
Original Assignee
Norton Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norton Healthcare Ltd filed Critical Norton Healthcare Ltd
Publication of AU2001232031A1 publication Critical patent/AU2001232031A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2001232031A 2000-02-11 2001-02-09 Novel uses of polyanionic polyglycosides in treating gut disorders Abandoned AU2001232031A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0003048.6A GB0003048D0 (en) 2000-02-11 2000-02-11 The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism
GB0003048 2000-02-11
PCT/GB2001/000506 WO2001058457A1 (en) 2000-02-11 2001-02-09 Novel uses of polyanionic polyglycosides in treating gut disorders

Publications (1)

Publication Number Publication Date
AU2001232031A1 true AU2001232031A1 (en) 2001-08-20

Family

ID=9885309

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001231987A Abandoned AU2001231987A1 (en) 2000-02-11 2001-01-29 Polyanionic polyglycosides in the treatment of autism
AU2001232031A Abandoned AU2001232031A1 (en) 2000-02-11 2001-02-09 Novel uses of polyanionic polyglycosides in treating gut disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2001231987A Abandoned AU2001231987A1 (en) 2000-02-11 2001-01-29 Polyanionic polyglycosides in the treatment of autism

Country Status (4)

Country Link
US (2) US20010039265A1 (en)
AU (2) AU2001231987A1 (en)
GB (1) GB0003048D0 (en)
WO (2) WO2001058456A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030008844A1 (en) * 2001-05-17 2003-01-09 Keryx Biopharmaceuticals, Inc. Use of sulodexide for the treatment of inflammatory bowel disease
US7354910B2 (en) 2001-10-18 2008-04-08 Seikagaku Kogyo Kabushiki Kaisha Agent for treating inflammatory bowel diseases
US20060074049A1 (en) * 2004-10-05 2006-04-06 Mitchell Krathwohl Use of heparinoids for treatment and prevention of dementia
IT1397247B1 (en) * 2009-05-14 2013-01-04 Fidia Farmaceutici NEW REGULATORY AGENTS OF CYTOKINIC ACTIVITY
KR20180107341A (en) * 2017-03-16 2018-10-02 차의과학대학교 산학협력단 Composition for the treatment and prevention of Leaky Gut Syndrome comprising Potassium-Competitive Acid Blocker as active component

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5158940A (en) * 1990-02-14 1992-10-27 The United States Government As Represented By The Secretary, Dhhs Use of suramin to treat rheumatologic diseases
US5580858A (en) * 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
US5952314A (en) * 1994-04-01 1999-09-14 Demichele; Stephen Joseph Nutritional product for a person having ulcerative colitis
AUPN261895A0 (en) * 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
UA72189C2 (en) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Aqueous suspensions of 9-hydroxy-risperidone fatty acid esters provided in submicron form
US6046179A (en) * 1998-04-17 2000-04-04 Murch; Simon Composition for and treatment of inflammatory bowel disease by colon administration of N-acetylglucosamine

Also Published As

Publication number Publication date
GB0003048D0 (en) 2000-03-29
US20010056078A1 (en) 2001-12-27
US20010039265A1 (en) 2001-11-08
WO2001058457A1 (en) 2001-08-16
WO2001058456A1 (en) 2001-08-16
AU2001231987A1 (en) 2001-08-20

Similar Documents

Publication Publication Date Title
AU2002223827A1 (en) Well treatment
AU2001245437A1 (en) Lightweight methods and compositions for well treating
AUPR105400A0 (en) Processes and compositions for water treatment
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
AU2001287023A1 (en) Plasma-derived-fibrin-based matrices and tissue
AU2001289684A1 (en) Glass-ceramics, process for their preparation and use
AUPR074500A0 (en) Treatment of t cell disorders
AU2002231206A1 (en) Treatment of depression
AU2001273972A1 (en) Hair treatment composition
AU2001239510A1 (en) Treatment of renal disorders
AU2001232031A1 (en) Novel uses of polyanionic polyglycosides in treating gut disorders
AU2001236929A1 (en) Surface treatment
AU2002360531A1 (en) Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2201
AU2000231423A1 (en) Specific therapeutic composition for treating aids
AUPQ884500A0 (en) Novel therapeutic molecules and uses therefor - III
AUPR069500A0 (en) Tissue modification
AU2002223679A1 (en) Hair treatment composition
AU2002256967A1 (en) Treating or reducing the risk of cardiovascular disease
AU2002360343A1 (en) Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804
AU2002342188A1 (en) Methods and compositions for treating flavivirus-mediated disease
AU2001253560A1 (en) Methods of treatment
AU2001292897A1 (en) Novel therapy
AU2002353915A1 (en) Methods and compositions for treating rotavirus-mediated disease
AU2001240017A1 (en) Human enzyme molecules
AUPR175600A0 (en) Novel treatment methods and compositions